Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed attachment file name title grouped question UIN question first answered answering member label
tabling member	label

Search

525084

	registered interest
	date	14/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Zero Hours Contracts
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of how England compares with other European countries in (1) one, (2) five, and (3) 10-year survival rates for patients diagnosed with metastatic kidney cancer.
	tabling member printed	Baroness Cumberlege
	uin	HL671
	answer	answer is ministerial correction date of answer 28/06/2016 answer text <p>No formal assessment has been made.</p><p> </p><p>Although cancer survival rates are at a record high and continue to improve, we know that we have to strive to be better. The independent Cancer Taskforce report, <em>Achieving World-Class Cancer Outcomes: A strategy for England 2015-2020</em>, published in July last year, recommends improvements across the cancer patient pathway. A copy of the report is attached.</p><p> </p><p>NHS England is currently working with partners across the health system to deliver the Cancer Taskforce’s recommendations. An implementation plan, <em>Achieving World-Class Cancer Outcomes: Taking the strategy forward</em>, was published on 12 May 2016 and we hope to see great progress as it is delivered. A copy of the implementation plan is attached.</p> answering member printed Lord Prior of Brampton attachment 1 file name Achieving World-Class Cancer Outcomes - A strategy for England 2015-2020.pdf title A strategy for England 2 file name Achieving world-class cancer outcomes -Taking the strategy forward.pdf title Taking the strategy forward question first answered 28/06/2016 13:31:37 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	2729 label Biography information for Baroness Cumberlege

525075

	registered interest
	date	14/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	High Speed 2 Railway Line
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, further to the Written Answers by Earl Howe on 31 March 2011 (WA 298–9) and by Lord Prior of Brampton on 24 March (HL7011), whether it is a condition of any licence granted by the Human Fertilisation and Embryology Authority that a sample of the stem cell lines derived must be deposited in the UK Stem Cell Bank either prior to or pursuant to publication; if not, why not; and if so, when each of the five human embryonic stem cell lines derived from blastocysts following pronuclear transfer as described in <i>Nature</i> (doi:10.1038/nature18303) were accordingly deposited.
	tabling member printed	Lord Alton of Liverpool
	uin	HL663
	answer	answer is ministerial correction date of answer 28/06/2016 answer text <p>It is a condition of all research licences granted by the Human Fertilisation and Embryology Authority (HFEA) that a sample of any stem cell line derived under that research project is deposited in the UK Stem Cell Bank. The HFEA has advised that it is not, therefore, necessary for a licence to additionally specify that any sample be deposited either prior to or pursuant to any publication about the derivation of stem cells under that project. It is a requirement of the UK Stem Cell Bank that applicants provide copies of any published scientific papers related to the derivation and/or characterisation of the stem cell line. The process for depositing cell lines in the UK Stem Cell Bank is a matter for the Bank itself to determine.</p> answering member printed Lord Prior of Brampton question first answered 28/06/2016 13:32:08 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	738 label Biography information for Lord Alton of Liverpool

525092

	registered interest
	date	14/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	European Railway Agency
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of whether the procurement exercises for hepatitis C medicines have resulted in lower costs to the NHS of hepatitis C medicines than those costs which informed the guidance set out in technology appraisals 363, 364 and 365 published by the National Institute for Health and Care Excellence.
	tabling member printed	Lord Mancroft
	uin	HL679
	answer	answer is ministerial correction date of answer 28/06/2016 answer text <p>The Department’s Commercial Medicines Unit manages, on behalf of English National Health Service secondary care, a tender strategy which establishes framework agreements for hepatitis C medicines under which prices are set. This programme commenced in August 2015 and has resulted in ongoing price reductions.</p><p> </p><p>In developing its recommendations on the use of daclatasvir (TA364) and ombitasvir–paritaprevir–ritonavir with or without dasabuvir (TA365) for the treatment of chronic hepatitis C, the National Institute for Health and Care Excellence (NICE) took into account the prices that had been agreed by the Commercial Medicines Unit at the time NICE’s guidance was being developed as the companies provided this information as part their evidence submissions to NICE. For the appraisal of ledipasvir-sofosbuvir for chronic hepatitis C (TA363), the company did not submit the equivalent information as evidence for consideration in the appraisal and NICE’s recommendations are based on the published list price for the drug. As a result of subsequent procurement exercises, these drugs may be available to the NHS at lower prices than when NICE developed its technology appraisal guidance.</p> answering member printed Lord Prior of Brampton grouped question UIN HL677 HL678 question first answered 28/06/2016 13:30:21 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	1833 label Biography information for Lord Mancroft

525091

	registered interest
	date	14/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	European GNSS Agency
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether savings realised through the procurement exercises for hepatitis C medicines were taken into account by the National Institute for Health and Care Excellence in its cost modelling in technology appraisals 363, 364 and 365.
	tabling member printed	Lord Mancroft
	uin	HL678
	answer	answer is ministerial correction date of answer 28/06/2016 answer text <p>The Department’s Commercial Medicines Unit manages, on behalf of English National Health Service secondary care, a tender strategy which establishes framework agreements for hepatitis C medicines under which prices are set. This programme commenced in August 2015 and has resulted in ongoing price reductions.</p><p> </p><p>In developing its recommendations on the use of daclatasvir (TA364) and ombitasvir–paritaprevir–ritonavir with or without dasabuvir (TA365) for the treatment of chronic hepatitis C, the National Institute for Health and Care Excellence (NICE) took into account the prices that had been agreed by the Commercial Medicines Unit at the time NICE’s guidance was being developed as the companies provided this information as part their evidence submissions to NICE. For the appraisal of ledipasvir-sofosbuvir for chronic hepatitis C (TA363), the company did not submit the equivalent information as evidence for consideration in the appraisal and NICE’s recommendations are based on the published list price for the drug. As a result of subsequent procurement exercises, these drugs may be available to the NHS at lower prices than when NICE developed its technology appraisal guidance.</p> answering member printed Lord Prior of Brampton grouped question UIN HL677 HL679 question first answered 28/06/2016 13:30:21 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	1833 label Biography information for Lord Mancroft

525090

	registered interest
	date	14/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Absent Voting: Northern Ireland
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether procurement exercises have taken place to reduce the prices paid by the NHS for new hepatitis C medicines.
	tabling member printed	Lord Mancroft
	uin	HL677
	answer	answer is ministerial correction date of answer 28/06/2016 answer text <p>The Department’s Commercial Medicines Unit manages, on behalf of English National Health Service secondary care, a tender strategy which establishes framework agreements for hepatitis C medicines under which prices are set. This programme commenced in August 2015 and has resulted in ongoing price reductions.</p><p> </p><p>In developing its recommendations on the use of daclatasvir (TA364) and ombitasvir–paritaprevir–ritonavir with or without dasabuvir (TA365) for the treatment of chronic hepatitis C, the National Institute for Health and Care Excellence (NICE) took into account the prices that had been agreed by the Commercial Medicines Unit at the time NICE’s guidance was being developed as the companies provided this information as part their evidence submissions to NICE. For the appraisal of ledipasvir-sofosbuvir for chronic hepatitis C (TA363), the company did not submit the equivalent information as evidence for consideration in the appraisal and NICE’s recommendations are based on the published list price for the drug. As a result of subsequent procurement exercises, these drugs may be available to the NHS at lower prices than when NICE developed its technology appraisal guidance.</p> answering member printed Lord Prior of Brampton grouped question UIN HL678 HL679 question first answered 28/06/2016 13:30:21 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	1833 label Biography information for Lord Mancroft

524998

	registered interest
	date	14/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS: Reorganisation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, pursuant to the Answer of 23 May 2016 to Question 37279, if he will make it his policy to ensure there is a formal public consultation on every Sustainability and Transformation Plan footprint.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	40553
	answer	answer is ministerial correction date of answer 28/06/2016 answer text <p>As set out in the NHS Shared Planning Guidance, published in December 2015, the success of Sustainability and Transformation Plans (STPs) will depend on having an open, engaging, and iterative process that involves patients, carers, citizens, clinicians, local community partners including the independent and voluntary sectors, and local government through health and wellbeing boards. The arm’s length bodies responsible for the NHS Five Year Forward View – NHS England, NHS Improvement, the Care Quality Commission, Public Health England, Health Education England and the National Institute for Health and Care Excellence – have asked for local engagement plans as part of the STP process, building where appropriate on existing engagement through health and wellbeing boards and other local arrangements.</p><p> </p><p>When plans are ready, normal rules around engagement and public consultation will apply. The arm’s length bodies will be holding conversations with each area to assess their plans for local engagement.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 28/06/2016 16:03:43 answering member 4020 label Biography information for George Freeman
	tabling member	3930 label Biography information for Caroline Lucas

525625

	registered interest
	date	15/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS Protect: Staff
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many people were employed by NHS Protect at each Civil Service pay grade in each year since 2010.
	tabling member constituency	Bristol North West
	tabling member printed	Charlotte Leslie
	uin	40811
	answer	answer is ministerial correction date of answer 28/06/2016 answer text <p>NHS Protect co-ordinates anti-crime work in the National Health Service in England. This not only includes investigations and prosecutions but also managing information and intelligence and, wherever possible, ensuring crime is deterred and prevented.</p><p> </p><table><tbody><tr><td><p><br></p></td><td><p>2010/11</p></td><td><p>2011/12</p></td><td><p>2012/13</p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td></tr><tr><td><p>Number of NHS Protect prosecutions</p></td><td><p>105</p></td><td><p>41</p></td><td><p>18</p></td><td><p>7</p></td><td><p>16</p></td><td><p>9</p></td></tr></tbody></table><p>Note:</p><ol><li>Not all prosecutions relate to cases where the investigation commenced in the year shown as complex investigations may take more than one year to conclude and, if appropriate, prosecute.</li></ol><p> </p><p>NHS Protect staff are employed on NHS Agenda for Change terms and conditions and the following table shows the number of NHS Protect staff by NHS pay scales.</p><p> </p><table><tbody><tr><td><p>Number of NHS Protect staff by grade</p></td><td><p>2010/11</p></td><td><p>2011/12</p></td><td><p>2012/13</p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td></tr><tr><td><p>Band 3</p></td><td><p>3</p></td><td><p>2</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td></tr><tr><td><p>Band 4</p></td><td><p>22</p></td><td><p>17</p></td><td><p>13</p></td><td><p>15</p></td><td><p>16</p></td><td><p>15</p></td></tr><tr><td><p>Band 5</p></td><td><p>23</p></td><td><p>34</p></td><td><p>28</p></td><td><p>30</p></td><td><p>30</p></td><td><p>30</p></td></tr><tr><td><p>Band 6</p></td><td><p>11</p></td><td><p>0</p></td><td><p>0</p></td><td><p>1</p></td><td><p>1</p></td><td><p>2</p></td></tr><tr><td><p>Band 7</p></td><td><p>106</p></td><td><p>87</p></td><td><p>78</p></td><td><p>78</p></td><td><p>85</p></td><td><p>81</p></td></tr><tr><td><p>Band 8a</p></td><td><p>30</p></td><td><p>32</p></td><td><p>34</p></td><td><p>34</p></td><td><p>35</p></td><td><p>30</p></td></tr><tr><td><p>Band 8b</p></td><td><p>13</p></td><td><p>10</p></td><td><p>11</p></td><td><p>10</p></td><td><p>10</p></td><td><p>10</p></td></tr><tr><td><p>Band 8c</p></td><td><p>6</p></td><td><p>5</p></td><td><p>6</p></td><td><p>6</p></td><td><p>6</p></td><td><p>3</p></td></tr><tr><td><p>Band 8d</p></td><td><p>1</p></td><td><p>1</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td><p>Band 9</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td></tr><tr><td><p>Associates</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td><td><p>2</p></td><td><p>1</p></td><td><p>1</p></td></tr><tr><td><p>Total</p></td><td><p>217</p></td><td><p>190</p></td><td><p>173</p></td><td><p>178</p></td><td><p>186</p></td><td><p>174</p></td></tr></tbody></table><p>Note:</p><ol><li>Associates are clinical specialists employed to provide advice and guidance in their area of expertise.</li></ol> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 40810 question first answered 28/06/2016 16:00:22 answering member 4020 label Biography information for George Freeman
	tabling member	3933 label Biography information for Charlotte Leslie

525624

	registered interest
	date	15/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS Protect
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many prosecutions have been instigated by NHS Protect in each year since 2010.
	tabling member constituency	Bristol North West
	tabling member printed	Charlotte Leslie
	uin	40810
	answer	answer is ministerial correction date of answer 28/06/2016 answer text <p>NHS Protect co-ordinates anti-crime work in the National Health Service in England. This not only includes investigations and prosecutions but also managing information and intelligence and, wherever possible, ensuring crime is deterred and prevented.</p><p> </p><table><tbody><tr><td><p><br></p></td><td><p>2010/11</p></td><td><p>2011/12</p></td><td><p>2012/13</p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td></tr><tr><td><p>Number of NHS Protect prosecutions</p></td><td><p>105</p></td><td><p>41</p></td><td><p>18</p></td><td><p>7</p></td><td><p>16</p></td><td><p>9</p></td></tr></tbody></table><p>Note:</p><ol><li>Not all prosecutions relate to cases where the investigation commenced in the year shown as complex investigations may take more than one year to conclude and, if appropriate, prosecute.</li></ol><p> </p><p>NHS Protect staff are employed on NHS Agenda for Change terms and conditions and the following table shows the number of NHS Protect staff by NHS pay scales.</p><p> </p><table><tbody><tr><td><p>Number of NHS Protect staff by grade</p></td><td><p>2010/11</p></td><td><p>2011/12</p></td><td><p>2012/13</p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td></tr><tr><td><p>Band 3</p></td><td><p>3</p></td><td><p>2</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td></tr><tr><td><p>Band 4</p></td><td><p>22</p></td><td><p>17</p></td><td><p>13</p></td><td><p>15</p></td><td><p>16</p></td><td><p>15</p></td></tr><tr><td><p>Band 5</p></td><td><p>23</p></td><td><p>34</p></td><td><p>28</p></td><td><p>30</p></td><td><p>30</p></td><td><p>30</p></td></tr><tr><td><p>Band 6</p></td><td><p>11</p></td><td><p>0</p></td><td><p>0</p></td><td><p>1</p></td><td><p>1</p></td><td><p>2</p></td></tr><tr><td><p>Band 7</p></td><td><p>106</p></td><td><p>87</p></td><td><p>78</p></td><td><p>78</p></td><td><p>85</p></td><td><p>81</p></td></tr><tr><td><p>Band 8a</p></td><td><p>30</p></td><td><p>32</p></td><td><p>34</p></td><td><p>34</p></td><td><p>35</p></td><td><p>30</p></td></tr><tr><td><p>Band 8b</p></td><td><p>13</p></td><td><p>10</p></td><td><p>11</p></td><td><p>10</p></td><td><p>10</p></td><td><p>10</p></td></tr><tr><td><p>Band 8c</p></td><td><p>6</p></td><td><p>5</p></td><td><p>6</p></td><td><p>6</p></td><td><p>6</p></td><td><p>3</p></td></tr><tr><td><p>Band 8d</p></td><td><p>1</p></td><td><p>1</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td><p>Band 9</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td></tr><tr><td><p>Associates</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td><td><p>2</p></td><td><p>1</p></td><td><p>1</p></td></tr><tr><td><p>Total</p></td><td><p>217</p></td><td><p>190</p></td><td><p>173</p></td><td><p>178</p></td><td><p>186</p></td><td><p>174</p></td></tr></tbody></table><p>Note:</p><ol><li>Associates are clinical specialists employed to provide advice and guidance in their area of expertise.</li></ol> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 40811 question first answered 28/06/2016 16:00:22 answering member 4020 label Biography information for George Freeman
	tabling member	3933 label Biography information for Charlotte Leslie

525623

	registered interest
	date	15/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Care Homes: Mortality Rates
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what correspondence his Department has received about data on adjusted deaths per beds rates in care homes since January 2014.
	tabling member constituency	Bristol North West
	tabling member printed	Charlotte Leslie
	uin	40809
	answer	answer is ministerial correction date of answer 28/06/2016 answer text <p>The Department has not received any such correspondence since January 2014.</p> answering member constituency North East Bedfordshire answering member printed Alistair Burt question first answered 28/06/2016 09:36:19 answering member 1201 label Biography information for Alistair Burt
	tabling member	3933 label Biography information for Charlotte Leslie

524975

	registered interest
	date	14/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS: Off-payroll Working
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Answer of 28 April 2016 to Question 35252, when he expects data to be published on the number of off-payroll staff within the scope of the HM Treasury guidance on senior off-payroll engagements in NHS foundation trusts in 2014-15.
	tabling member constituency	Dewsbury
	tabling member printed	Paula Sherriff
	uin	40584
	answer	answer is ministerial correction date of answer 28/06/2016 answer text <p>NHS Improvement will publish this information as soon as possible.</p> answering member constituency North East Bedfordshire answering member printed Alistair Burt question first answered 28/06/2016 09:35:16 answering member 1201 label Biography information for Alistair Burt
	tabling member	4426 label Biography information for Paula Sherriff